Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) announced a poster presentation at the Seventh International Cancer Immunotherapy Conference 2023. The presentation involves TNX-1700 in preclinical colorectal cancer models. The conference will be held in Milan, Italy, from September 20-23, 2023.
September 14, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tonix Pharmaceuticals' announcement of their presentation at the International Cancer Immunotherapy Conference could potentially increase investor interest in the company and its colorectal cancer drug, TNX-1700.
The announcement of Tonix Pharmaceuticals' presentation at a major conference could potentially increase visibility and interest in the company and its drug, TNX-1700. This could lead to increased investor interest and potentially a short-term increase in the company's stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100